Bill Burkoth, MBA is Executive Director, WWBD and Senior Partner at Pfizer Ventures. Since joining Pfizer in early 2004, Bill has played an instrumental role in making and managing numerous venture capital investments in companies spanning the healthcare sector. He currently has responsibility for Pfizer’s investments in 4D Molecular Therapeutics, AMRA, Biodesy, G-Con Manufacturing, NeuMoDx Molecular, Palleon Pharma, RefleXion Medical, Second Genome, and Strata Oncology. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and FinHealth Gestão de Recursos S.A. (Rio, Brazil).
Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital.
Bill received a BA in chemistry from Whitman College and an MBA from Columbia Business School.